A Study of Inebilizumab Efficacy and Safety in IgG4- Related Disease

Status:
Recruiting

Trial end date:
2024-06-01

Target enrollment:

Participant gender:

This study aims to define the efficacy and safety of inebilizumab for the prevention of flare of IgG4-related disease (IgG4-RD).

Phase 3

Viela Bio